Dr. Wolchok is chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center (MSK). His insight and innovation have placed him at the leading edge of cancer immunotherapy in two different roles: An active clinician-scientist exploring innovative immunotherapeutic strategies in laboratory models, and a principal investigator in numerous pivotal clinical trials. His specific research interest is the pre-clinical and early clinical development of novel immunologic therapies. Most recently, Dr. Wolchok has initiated several clinical trials using plasmid DNA vaccines for patients with melanoma. He’s been involved in the development of the DNA vaccine program at every level – from initial studies in mouse models, through all levels of regulatory review, and now as principal investigator of the clinical trials.